US20130344116A1 - Oral particle consisting of an amorphous structure and a submicron domain - Google Patents

Oral particle consisting of an amorphous structure and a submicron domain Download PDF

Info

Publication number
US20130344116A1
US20130344116A1 US13/663,350 US201213663350A US2013344116A1 US 20130344116 A1 US20130344116 A1 US 20130344116A1 US 201213663350 A US201213663350 A US 201213663350A US 2013344116 A1 US2013344116 A1 US 2013344116A1
Authority
US
United States
Prior art keywords
drug
particle
amorphous structure
oral
submicron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/663,350
Inventor
David Wong
James A. Lee
Peter P. Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magnifica Inc
Original Assignee
Magnifica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magnifica Inc filed Critical Magnifica Inc
Priority to US13/663,350 priority Critical patent/US20130344116A1/en
Priority to US13/680,070 priority patent/US20130344148A1/en
Publication of US20130344116A1 publication Critical patent/US20130344116A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

  • the present invention relates to the compositions and methods of the preparation of an oral particle comprising an amorphous structure and a submicron domain, wherein both amorphous structure and submicron domain comprise a drug, and wherein the particle shows crystalline property.
  • Solid dispersion has been prepared by solvent evaporation, by spray drying, by spraying drug solution onto a carrier, by twin screw extrusion, by melt fusion, by mechanical admixture such as by ball milling and by mechanical admixture at an elevated but non-melting temperature, as described in U.S. Pat. No. 6,706,283.
  • Pat. No. 5,028,433 teaches a readily absorbable drug formulation by incorporating to a water-soluble or enteric polymer.
  • U.S. Pat. No. 5,514,663 teaches a composition comprising 3-15 mg of sennosides, wherein the sennosides are in a solid dispersion.
  • U.S. Pat. No. 5,631,022 teaches a composition wherein the drug is in a solid dispersion in a water-soluble carrier.
  • U.S. Pat. No. 5,651,983, U.S. Pat. No. 5,843,479 and U.S. Pat. No. 5,656,290 teach a solid dispersion of bisacodyl on a hydrophilic substrate.
  • 6,174,873 suggests a solid dispersion comprising a carrier selected from the group consisting of polyethylene glycol, polyvinylpyrrolldone, hydroxypropylmethyl cellulose, phosphatidylcholine, polyoxyethylene hydrogenated castor oil, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, hydroxypropylmethylcellulose, ethyl cellulose and stearic acid.
  • a carrier selected from the group consisting of polyethylene glycol, polyvinylpyrrolldone, hydroxypropylmethyl cellulose, phosphatidylcholine, polyoxyethylene hydrogenated castor oil, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, hydroxypropylmethylcellulose, ethyl cellulose and stearic acid.
  • U.S. Pat. No. 6,706,283 and other articles U.S. Pat. No. 5,162,117 teaches a controlled release tablet of flutamide.
  • the core comprises 20-80 percent of flutamide and a carrier capable of forming a solid dispersion with flutamide.
  • U.S. Pat. No. 5,773,025 teaches a bioavailable sustained release oral solid dosage form comprising agglomerated particles of a therapeutically active medicament in amorphous form.
  • U.S. Pat. No. 5,932,245 suggests a dosage formulation that provides for the release of nanoparticles, wherein the nanoparticles have inner phase and outer phase. Both phases are charged.
  • U.S. Pat. No. 5,972,389 teaches a controlled release oral drug dosage form for releasing a vesicle-containing drug into the stomach, duodenum, and intestinal areas which contain Peyer's patches of a patient, wherein said drug is soluble, but is rendered sparingly soluble when contained in said vesicle, and wherein the vesicle is a member selected from the group consisting of a liposome, nanoparticle, nanosphere and nanocapsule.
  • U.S. Pat. No. 7,803,748 teaches a composition of nanoparticles wherein the nanoparticles enhance paracellular transport of at least one bioactive agent and wherein said nanoparticles are further configured in a tablet form with one or more excipients.
  • a flexible formulation comprising an amorphous structure and submicron particle may allow a reduction of instability during storage or even improved bioavailability compared to conventional tablet dosage forms.
  • the inventors have found methods to prepare solid compositions comprising an amorphous structure and a submicron domain for water insoluble drugs, wherein the ratio of the amorphous structure to the submicron domain is from 0.1:5 to 1:1, preferably 1:50 to 1:4.
  • the present invention relates to a particle composition
  • a particle composition comprising an amorphous structure and a submicron domain, and wherein the amorphous structure is a molecular dispersion of a drug in a solid polymeric matrix and the submicron domain is a submicron drug particle.
  • the present invention relates to a tablet composition
  • a tablet composition comprising a particle and a pharmaceutically acceptable carrier, wherein the particle comprises an amorphous structure and a submicron domain, and wherein the amorphous structure is a molecular solid dispersion of a drug in a polymeric matrix and the submicron domain is a submicron drug particle.
  • the tablet may further comprise a micronized drug particle.
  • the pharmaceutically acceptable carrier comprises a binder, a filler, a lubricant, and optionally a gelling agent, a glidant and an anti-sticking agent.
  • the tablet composition may exhibit crystalline properties as observed under a polarized microscope.
  • the tablet composition is optionally coated with a film for cosmetic or other purposes.
  • the tablet composition may further comprise a sweetener.
  • the invention relates to a method for preparing a particle comprising an amorphous structure and a submicron domain, wherein the particle is prepared by dissolving a drug and a polymer in a co-solvent, adding a non-solvent to precipitate a portion of the drug, drying and milling of the resulting mass.
  • the particle is prepared by dissolving a drug and a polymer in a co-solvent, adding a non-solvent to precipitate a portion of the drug, spraying and drying this suspension onto a micronized drug particle.
  • the particle is made by combining a drug solid dispersion and a drug nanoparticle. Moreover, this method is tedious, time and energy-consumption.
  • drug means a compound intended for use in diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals.
  • drug means a compound intended for use in diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals.
  • drugs, therapeutics, actives, active ingredient and biological active are inter-changeable.
  • pharmaceutically acceptable is meant a carrier comprised of a material that is not biologically or otherwise undesirable.
  • hydrophilic describes that something ‘likes water’, i.e. a hydrophilic molecule is one that typically is electrically polarized and capable of forming hydrogen bonds with water molecules.
  • soluble soluble
  • lightly soluble soluble
  • sparingly-soluble insoluble
  • insoluble soluble
  • a substance is said to be soluble if more than 0.1 g of the substance dissolves in 100 mL solvent.
  • the present invention can be applied to drugs sparingly soluble in water, drugs slightly soluble in water, drugs very slightly soluble in water and drugs practically insoluble in water. (See Table 1)
  • amphiphilic in the present context describes a chemical is able to dissolve in an aqueous medium and an organic solvent.
  • polyvinylpyrrolidone and polyethylene glycol are considered as amphiphilic polymers, as they dissolve in water and in most alcohols.
  • Solid dispersion in the present context, denotes the drug molecules dispersed in a polymeric matrix in a solid state.
  • micronized domain refers to a micronized drug particle sprayed or coated with a solid dispersion—submicron domain mixture.
  • solvent is a liquid that dissolves solids resulting in a solution.
  • Non-solvent is a substance incapable of dissolving a given component of a mixture.
  • water is a non-solvent to water-insoluble drugs.
  • the present invention provides an oral composition and methods for preparing such compositions.
  • the oral solid compositions are in the form of particles and tablets and may have one or more of the following characteristics: (1) comprising an amorphous structure of a drug substance, a submicron domain of a drug substance, (2) providing fast or slow release; and (3) optionally coated for appearance, tasking masking, extended-release or delayed-release.
  • this invention provides an oral particle composition comprising an amorphous structure and a submicron domain, wherein the amorphous structure comprises drug molecules dispersed in a polymer matrix, and wherein the submicron domain is a submicron drug particle. Further, this invention also provides an oral particle composition essentially consisting of an amorphous structure and a submicron domain, wherein the amorphous structure is a drug molecule dispersed in a polymer matrix, and wherein the submicron domain consists essentially of a drug, wherein the polymer is amphiphilic and selected from the group consisting of polyvinylpyrrolidone and polyethylene glycol. Under a polarized microscope, the composition shows crystalline properties.
  • the desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4.
  • the desired average particle diameter is mesh 12 (1680 microns) and mesh 100 (149 microns), and the most preferred average particle diameter is between mesh 20 (841 microns) and mesh 100 (149 microns).
  • the desired drug solubility in the application is described in paragraph [017].
  • this invention provides an oral tablet composition for pharmaceutical use, comprising a particle described in paragraph [023], wherein the particle may further comprise a micronized drug domain, wherein the tablet composition may further comprise a micronized drug particle and wherein the a pharmaceutically acceptable carrier comprising a binder, a filler, an extended-release aid, glidant and a lubricant alone or in any combinations.
  • the composition is optionally film-coated.
  • Solvent-based method is one of the popular ways to prepare solid dispersion.
  • a co-solvent is used to intimately dissolve a drug and carrier molecules together to form a solution, and then the solvent is removed by evaporation.
  • the resulting solid is a dispersion of drug molecules in the carrier molecules.
  • a non-solvent (with respect to the drug; miscible to the solvent) is added to the drug-carrier solution.
  • the solution becomes saturated and a portion of the drug precipitates out.
  • the solvent is removed by evaporation to achieve a solid state comprising an amorphous structure and submicron domains.
  • the particle comprising (or essentially consisting of) an amorphous structure and a submicron domain can be obtained by the following steps: dissolving a drug and a polymer in a co-solvent, adding a non-solvent to precipitate a portion of the drug to form a suspension, drying the suspension by air-drying, a spray-dryer or a rotary evaporator, and then milling of the dried mass to form the particles.
  • the amount of the crystalline structure is inversely proportional to the amount of polymer used in the preparation.
  • Alternative method is a direct combination of a drug nano-particle and a drug polymeric dispersion.
  • the preparation of drug particles in nano-scale is tedious and energy-consumption. Under a polarized microscope, the composition shows crystalline properties.
  • the desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4.
  • the pharmaceutical tablet composition according to the present invention can be obtained by (1) blending and then (2) compressing the particle comprising the amorphous structure and submicron domains with a pharmaceutically acceptable carrier.
  • the composition can be an extended release tablet or an immediate-release tablet.
  • the composition may further comprise a sweetener and another drug. Under a polarized microscope, the composition shows crystalline properties.
  • the desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4.
  • the composition may also optionally film-coated for functional or cosmetic purposes.
  • the functional purposes of the film include moisture-barrier, extended-release, delayed-release, taste-masking etc.
  • the oral particle essentially consisting of an amorphous structure and a submicron domain, wherein the amorphous structure comprising a drug and a polymer, and wherein the submicron domain essentially consisting of a drug.
  • the desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4.
  • the polymer is preferred to be amphiphilic, the preferred polymer is selected from the group consisting of polyethylene glycol and polyvinylpyrrolidone.
  • the solubility of the polymer is preferred to be pH sensitive. Examples include but not limited to amino methacrylate copolymer and poly(methacylic acid-co-methyl methacrylate).
  • the preferred average diameter of the submicron domain is about 100 nm or smaller. The preferred average diameter of the particle is from mesh 20 to mesh 100. And, there is a limitation for the solubility of the drug, please, see paragraph [017].
  • the composition comprises: (1) a particle essentially consisting of an amorphous structure and a submicron domain, wherein the amorphous structure comprising a water-insoluble drug and a polymer, and wherein the submicron domain essentially consisting of a water-insoluble drug, (2) a pharmaceutical carrier, and optionally (3) a micronized drug particle.
  • the desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4.
  • the polymer is preferred to be amphiphilic, the preferred polymer is selected from a group consisting of polyethylene glycol and polyvinylpyrrolidone.
  • the solubility of the polymer is preferred to be pH sensitive.
  • examples include but not limited to amino methacrylate copolymer and poly(methacylic acid-co-methyl methacrylate).
  • the preferred average diameter of the submicron domain is about 100 nm or smaller.
  • the pharmaceutical carrier is selected from a group consisting of retarding agent, binder, filler, diluents, lubricant or a mixture thereof, the tablet composition is optionally film-coated for moisture barrier, appearance and modified-release.
  • the particle essentially consisting of an amorphous structure and a submicron domain is prepared by dissolving the drug and a polymer in a co-solvent, adding a non-solvent to precipitate a portion of drug, drying and then milling of the resulting mass.
  • the particle essentially consisting of an amorphous structure and a submicron domain is simply prepared by adding a drug polymeric dispersion onto a drug nanoparticle.
  • the present invention can be applied to drugs sparingly soluble in water, drugs slightly soluble in water, drugs very slightly soluble in water and drugs practically insoluble in water.
  • examples include but not limited to acetaminophen, alprazolam, atorvastatin calcium, betamethasone acetate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, buprenorphine hydrochloride, butoconazole nitrate, caffeine, calcitriol, carbamazepine, carprofen, celecoxib, cilostazol, clarithromycin, clobetasol Propionate, clofibrate, clopidogrel bisulfate, clotrimazole, dactinomycin, danazol, dapsone, desoximetasone, dexamethasone acetate, dextromethorphan, diazepam, efavirenz, erythro
  • excipient employed will depend upon how much active agent is to be used. One excipient can perform multi-functionally. Examples of excipients include but not limited to retarding agent, binder, filler, diluents, lubricant or a mixture thereof.
  • Retarding agent is any substance retards the drug release to produce the controlled-release effect.
  • retarding agent include but not limited to wax, hydrogel polymer, and many other water-insoluble materials.
  • the hydrogel polymer is the key retarding agent.
  • Binders include, but are not limited to, starches such as potato starch, wheat starch, corn starch; microcrystalline cellulose; celluloses such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, sodium carboxy methylcellulose; natural gums like acacia, alginic acid, guar gum; liquid glucose, dextrin, povidone, syrup, polyethylene oxide, polyvinyl pyrrolidone, poly-N-vinyl amide, polyethylene glycol, gelatin, poly propylene glycol, tragacanth, combinations thereof and other materials known to one of ordinary skill in the art and mixtures thereof.
  • Fillers or diluents which include, but are not limited to sugar, dextrates, dextrin, dextrose, fructose, lactitol, mannitol, sucrose, starch, lactose, xylitol, sorbitol, talc, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic or tribasic, calcium sulphate, and the like can be used.
  • Lubricants may be selected from, but are not limited to, those conventionally known in the art such as magnesium, aluminum or calcium or zinc stearate, polyethylene glycol, glyceryl behenate, mineral oil, sodium stearyl fumarate, stearic acid, hydrogenated vegetable oil and talc.
  • Glidants include, but are not limited to, silicon dioxide; magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate, calcium silicate, magnesium silicate, colloidal silicon dioxide, silicon hydrogel and other materials known to one of ordinary skill in the art.
  • Sweeteners may also be added to the composition.
  • sweeteners include but not limited to glucose, stevia extracts, acesulfame potassium, aspartame, neotame, saccharin and sucralose.
  • the pharmaceutical dosage form of the invention may also be optionally coated with moisture-barrier film, sugar coating, enteric coating, bioadhesive coating and other coatings known in the art. These coatings help pharmaceutical formulations to release the drug at the required site of action.
  • the additional coating prevents the dosage from contacting the mouth or esophagus.
  • the additional coating remains intact until reaching the small intestine or colon (e.g., an enteric coating).
  • These coatings comprise one or more excipients selected from a group consisting of coating agents, plasticizers, channeling agents, opacifiers, taste-masking agents, fillers, polishing agents, coloring agents, anti-tacking agents and the like.
  • Coating agents which are useful in the coating process, include, but are not limited to, polysaccharides such as maltodextrin, alkyl celluloses such as methyl or ethyl cellulose, cellulose acetate, hydroxyalkylcelluloses (e.g. hydroxypropylcellulose or hydroxypropylmethylcelluloses); polyvinylpyrrolidone, acacia, corn, sucrose, gelatin, shellac, cellulose acetate pthalate, lipids, synthetic resins, acrylic polymers, OPADRY® coating systems, polyvinyl alcohol (PVA), copolymers of vinylpyrrolidone and vinyl acetate (e.g.
  • PVA polyvinyl alcohol
  • PLASDONE® polymers based on methacrylic acid
  • EUDRAGIT® polymers based on methacrylic acid
  • Additives can be included along with the film formers to obtain satisfactory films.
  • These additives can include plasticizers such as dibutyl phthalate, triethyl citrate, polyethylene glycol (PEG) and the like, channeling agents such as surfactants, short-chain water-soluble polymers, salts and the like, antitacking agents such as talc, stearic acid, magnesium stearate and colloidal silicon dioxide and the like, fillers such as talc, precipitated calcium carbonate, polishing agents such as Beeswax, carnauba wax, synthetic chlorinated wax and opacifying agents such as titanium dioxide and the like. All these excipients can be used at levels well known to the persons skilled in the art.
  • Duloxetine hydrochloride and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with a pharmaceutically acceptable carrier, compressed into a tablet.
  • metaxalone and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with another portion of metaxalone and a pharmaceutically acceptable carrier, compressed into a tablet.
  • a portion of clopidogrel bisulfate and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with another portion of metaxalone and a pharmaceutically acceptable carrier, compressed into a tablet.
  • Duloxetine hydrochloride and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with bupropion hydrochloride and a pharmaceutically acceptable carrier, compressed into a tablet.
  • Duloxetine hydrochloride and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with a tranquilizer and a pharmaceutically acceptable carrier, compressed into a tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to compositions and methods of the preparation of an oral particle essentially consisting of an amorphous structure and a submicron domain, wherein both amorphous structure and submicron domain comprise a drug, and wherein the particle shows crystalline property. The desired ratio of the amorphous structure to the submicron domain is between 0.1:5 and 1:1. And, the desired average particle diameter is between mesh 12 (1680 microns) and mesh 100 (149 microns).

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of and priority to U.S. Non-Provisional application Ser. No. 13/533,410, filed on Jun. 26, 2012 which is incorporated herein by reference.
    • TECHNICAL FIELD
  • The present invention relates to the compositions and methods of the preparation of an oral particle comprising an amorphous structure and a submicron domain, wherein both amorphous structure and submicron domain comprise a drug, and wherein the particle shows crystalline property.
    • BACKGROUND OF THE INVENTION
  • Poor water-solubility is known to be a limiting factor bioavailability. Many attempts have been done with the aim to improving the bioavailability of water-insoluble and water-sparingly soluble drugs. Most such formulations were immediate release in nature as this generally maximizes the amount of drug absorbed. Micronization, solid dispersion and micelle-formation are common techniques used to enhance the drug solubility.
  • Solid dispersion has been prepared by solvent evaporation, by spray drying, by spraying drug solution onto a carrier, by twin screw extrusion, by melt fusion, by mechanical admixture such as by ball milling and by mechanical admixture at an elevated but non-melting temperature, as described in U.S. Pat. No. 6,706,283.
  • Solid dispersion has been suggested by several U.S. patents. U.S. Pat. No. 5,281,420 teaches compositions in dosage form comprising a solid dispersion which is a solidified melt mixture consisting of tebufelone, a poloxamer surfactant and other components. The other components are miscible with a melt mixture of components. U.S. Pat. No. 7,273,624 has taught a composition of an active ingredient embedded amorphously in particular. The author emphasizes that there are essentially no crystalline contents of any constituent in their particular embodiment. U.S. Pat. No. 4,654,296 teaches a solid dispersion composition containing dihydropyridien A uniformly dispersed in hydroxypropylmethyl cellulose. U.S. Pat. No. 5,028,433 teaches a readily absorbable drug formulation by incorporating to a water-soluble or enteric polymer. U.S. Pat. No. 5,514,663 teaches a composition comprising 3-15 mg of sennosides, wherein the sennosides are in a solid dispersion. U.S. Pat. No. 5,631,022 teaches a composition wherein the drug is in a solid dispersion in a water-soluble carrier. U.S. Pat. No. 5,651,983, U.S. Pat. No. 5,843,479 and U.S. Pat. No. 5,656,290 teach a solid dispersion of bisacodyl on a hydrophilic substrate. U.S. Pat. No. 6,174,873 suggests a solid dispersion comprising a carrier selected from the group consisting of polyethylene glycol, polyvinylpyrrolldone, hydroxypropylmethyl cellulose, phosphatidylcholine, polyoxyethylene hydrogenated castor oil, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, hydroxypropylmethylcellulose, ethyl cellulose and stearic acid.
  • Application of solid dispersion on oral extended release tablet for treating diseases has been described in U.S. Pat. No. 6,706,283 and other articles. U.S. Pat. No. 5,162,117 teaches a controlled release tablet of flutamide. The core comprises 20-80 percent of flutamide and a carrier capable of forming a solid dispersion with flutamide. U.S. Pat. No. 5,773,025 teaches a bioavailable sustained release oral solid dosage form comprising agglomerated particles of a therapeutically active medicament in amorphous form.
  • Several articles teach tablet composition comprising nano- or submicron particles. U.S. Pat. No. 5,932,245 suggests a dosage formulation that provides for the release of nanoparticles, wherein the nanoparticles have inner phase and outer phase. Both phases are charged. U.S. Pat. No. 5,972,389 teaches a controlled release oral drug dosage form for releasing a vesicle-containing drug into the stomach, duodenum, and intestinal areas which contain Peyer's patches of a patient, wherein said drug is soluble, but is rendered sparingly soluble when contained in said vesicle, and wherein the vesicle is a member selected from the group consisting of a liposome, nanoparticle, nanosphere and nanocapsule. U.S. Pat. No. 7,803,748 teaches a composition of nanoparticles wherein the nanoparticles enhance paracellular transport of at least one bioactive agent and wherein said nanoparticles are further configured in a tablet form with one or more excipients.
  • It is known that unstable solid dispersion converts to a crystal form over the time, while nano-particle aggregation or even fusion may happen during the process or storage. Thus, there remains a need for a novel pharmaceutical dosage structure and/or composition comprising an amorphous structure and submicron particle allowing more flexibility for formulation development. A flexible formulation comprising an amorphous structure and submicron particle may allow a reduction of instability during storage or even improved bioavailability compared to conventional tablet dosage forms.
    • BRIEF SUMMARY OF THE INVENTION
  • The inventors have found methods to prepare solid compositions comprising an amorphous structure and a submicron domain for water insoluble drugs, wherein the ratio of the amorphous structure to the submicron domain is from 0.1:5 to 1:1, preferably 1:50 to 1:4.
  • Accordingly, in one aspect the present invention relates to a particle composition comprising an amorphous structure and a submicron domain, and wherein the amorphous structure is a molecular dispersion of a drug in a solid polymeric matrix and the submicron domain is a submicron drug particle.
  • In a further aspect, the present invention relates to a tablet composition comprising a particle and a pharmaceutically acceptable carrier, wherein the particle comprises an amorphous structure and a submicron domain, and wherein the amorphous structure is a molecular solid dispersion of a drug in a polymeric matrix and the submicron domain is a submicron drug particle. The tablet may further comprise a micronized drug particle. The pharmaceutically acceptable carrier comprises a binder, a filler, a lubricant, and optionally a gelling agent, a glidant and an anti-sticking agent. The tablet composition may exhibit crystalline properties as observed under a polarized microscope. The tablet composition is optionally coated with a film for cosmetic or other purposes. And also, the tablet composition may further comprise a sweetener.
  • In a further aspect, the invention relates to a method for preparing a particle comprising an amorphous structure and a submicron domain, wherein the particle is prepared by dissolving a drug and a polymer in a co-solvent, adding a non-solvent to precipitate a portion of the drug, drying and milling of the resulting mass. In an alternative method, the particle is prepared by dissolving a drug and a polymer in a co-solvent, adding a non-solvent to precipitate a portion of the drug, spraying and drying this suspension onto a micronized drug particle. Alternatively, the particle is made by combining a drug solid dispersion and a drug nanoparticle. Moreover, this method is tedious, time and energy-consumption.
    • DETAILED DESCRIPTION OF THE INVENTION Definitions
  • A used herein, the term “drug” means a compound intended for use in diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals. The terms drugs, therapeutics, actives, active ingredient and biological active are inter-changeable.
  • “Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.
  • Singular forms included in the claims such as “a”, “an” and “the” include the plural reference unless expressly stated or the context clearly indicates otherwise.
  • By “pharmaceutically acceptable” is meant a carrier comprised of a material that is not biologically or otherwise undesirable.
  • In the present context, the term “hydrophilic” describes that something ‘likes water’, i.e. a hydrophilic molecule is one that typically is electrically polarized and capable of forming hydrogen bonds with water molecules.
  • The terms “soluble”, “slightly soluble”, “sparingly-soluble” and “insoluble” are relative. In general, a substance is said to be soluble if more than 0.1 g of the substance dissolves in 100 mL solvent. The present invention can be applied to drugs sparingly soluble in water, drugs slightly soluble in water, drugs very slightly soluble in water and drugs practically insoluble in water. (See Table 1)
  • TABLE 1
    Values for estimating drug solubility based upon “USP definition”
    Appropriate Volume of Solvent In Milliliters Per Gram
    Descriptive Term of Solute
    Very soluble Less than 1 part solvent needed to dissolve 1 part
    solute
    Freely soluble From 1 to 10 parts solvent needed to dissolve 1 part
    solute
    Soluble From 10 to 30 parts solvent needed to dissolve 1 part
    solute
    Sparingly soluble From 30 to 100 parts solvent needed to dissolve 1
    part solute
    Slightly soluble From 100 to 1000 parts solvent needed to dissolve 1
    part solute
    Very slightly From 1000 to 10,000 parts solvent needed to dissolve
    soluble 1 part solute
    Practically More than 10,000 parts solvent needed to dissolve 1
    insoluble part solute
  • In the present context, the term “amphiphilic” in the present context describes a chemical is able to dissolve in an aqueous medium and an organic solvent. For example, polyvinylpyrrolidone and polyethylene glycol are considered as amphiphilic polymers, as they dissolve in water and in most alcohols.
  • The terms “solid dispersion”, “amorphous domain” and “amorphous structure” are interchangeable. Solid dispersion, in the present context, denotes the drug molecules dispersed in a polymeric matrix in a solid state.
  • The term “micronized domain” refers to a micronized drug particle sprayed or coated with a solid dispersion—submicron domain mixture.
  • In this context, solvent is a liquid that dissolves solids resulting in a solution. Non-solvent is a substance incapable of dissolving a given component of a mixture. Thus, water is a non-solvent to water-insoluble drugs.
    • The Invention
  • The present invention provides an oral composition and methods for preparing such compositions. The oral solid compositions are in the form of particles and tablets and may have one or more of the following characteristics: (1) comprising an amorphous structure of a drug substance, a submicron domain of a drug substance, (2) providing fast or slow release; and (3) optionally coated for appearance, tasking masking, extended-release or delayed-release.
  • Accordingly, this invention provides an oral particle composition comprising an amorphous structure and a submicron domain, wherein the amorphous structure comprises drug molecules dispersed in a polymer matrix, and wherein the submicron domain is a submicron drug particle. Further, this invention also provides an oral particle composition essentially consisting of an amorphous structure and a submicron domain, wherein the amorphous structure is a drug molecule dispersed in a polymer matrix, and wherein the submicron domain consists essentially of a drug, wherein the polymer is amphiphilic and selected from the group consisting of polyvinylpyrrolidone and polyethylene glycol. Under a polarized microscope, the composition shows crystalline properties. The desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4. The desired average particle diameter is mesh 12 (1680 microns) and mesh 100 (149 microns), and the most preferred average particle diameter is between mesh 20 (841 microns) and mesh 100 (149 microns). The desired drug solubility in the application is described in paragraph [017].
  • In a further aspect, this invention provides an oral tablet composition for pharmaceutical use, comprising a particle described in paragraph [023], wherein the particle may further comprise a micronized drug domain, wherein the tablet composition may further comprise a micronized drug particle and wherein the a pharmaceutically acceptable carrier comprising a binder, a filler, an extended-release aid, glidant and a lubricant alone or in any combinations. The composition is optionally film-coated.
  • Solvent-based method is one of the popular ways to prepare solid dispersion. In such method, a co-solvent is used to intimately dissolve a drug and carrier molecules together to form a solution, and then the solvent is removed by evaporation. The resulting solid is a dispersion of drug molecules in the carrier molecules. In the present invention, a non-solvent (with respect to the drug; miscible to the solvent) is added to the drug-carrier solution. As the solvency to the drug decreases, the solution becomes saturated and a portion of the drug precipitates out. At this stage, the solvent is removed by evaporation to achieve a solid state comprising an amorphous structure and submicron domains. Thus, the particle comprising (or essentially consisting of) an amorphous structure and a submicron domain can be obtained by the following steps: dissolving a drug and a polymer in a co-solvent, adding a non-solvent to precipitate a portion of the drug to form a suspension, drying the suspension by air-drying, a spray-dryer or a rotary evaporator, and then milling of the dried mass to form the particles. The amount of the crystalline structure is inversely proportional to the amount of polymer used in the preparation. Alternative method is a direct combination of a drug nano-particle and a drug polymeric dispersion. However, the preparation of drug particles in nano-scale is tedious and energy-consumption. Under a polarized microscope, the composition shows crystalline properties. The desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4.
  • The pharmaceutical tablet composition according to the present invention can be obtained by (1) blending and then (2) compressing the particle comprising the amorphous structure and submicron domains with a pharmaceutically acceptable carrier. In this invention, the composition can be an extended release tablet or an immediate-release tablet. The composition may further comprise a sweetener and another drug. Under a polarized microscope, the composition shows crystalline properties. The desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4. The composition may also optionally film-coated for functional or cosmetic purposes. The functional purposes of the film include moisture-barrier, extended-release, delayed-release, taste-masking etc.
  • In one embodiment, the oral particle essentially consisting of an amorphous structure and a submicron domain, wherein the amorphous structure comprising a drug and a polymer, and wherein the submicron domain essentially consisting of a drug. The desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4. The polymer is preferred to be amphiphilic, the preferred polymer is selected from the group consisting of polyethylene glycol and polyvinylpyrrolidone. In another embodiment, the solubility of the polymer is preferred to be pH sensitive. Examples include but not limited to amino methacrylate copolymer and poly(methacylic acid-co-methyl methacrylate). The preferred average diameter of the submicron domain is about 100 nm or smaller. The preferred average diameter of the particle is from mesh 20 to mesh 100. And, there is a limitation for the solubility of the drug, please, see paragraph [017].
  • In a tablet embodiment, the composition comprises: (1) a particle essentially consisting of an amorphous structure and a submicron domain, wherein the amorphous structure comprising a water-insoluble drug and a polymer, and wherein the submicron domain essentially consisting of a water-insoluble drug, (2) a pharmaceutical carrier, and optionally (3) a micronized drug particle. For the particle (1) of the tablet embodiment, the desired ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1, and more preferably 1:50 to 1:4. The polymer is preferred to be amphiphilic, the preferred polymer is selected from a group consisting of polyethylene glycol and polyvinylpyrrolidone. In another tablet embodiment, the solubility of the polymer is preferred to be pH sensitive. Examples include but not limited to amino methacrylate copolymer and poly(methacylic acid-co-methyl methacrylate). The preferred average diameter of the submicron domain is about 100 nm or smaller.
  • In all tablet embodiments discussed, the pharmaceutical carrier is selected from a group consisting of retarding agent, binder, filler, diluents, lubricant or a mixture thereof, the tablet composition is optionally film-coated for moisture barrier, appearance and modified-release.
  • In all embodiments, the particle essentially consisting of an amorphous structure and a submicron domain is prepared by dissolving the drug and a polymer in a co-solvent, adding a non-solvent to precipitate a portion of drug, drying and then milling of the resulting mass. Alternatively, the particle essentially consisting of an amorphous structure and a submicron domain is simply prepared by adding a drug polymeric dispersion onto a drug nanoparticle.
  • The present invention can be applied to drugs sparingly soluble in water, drugs slightly soluble in water, drugs very slightly soluble in water and drugs practically insoluble in water. Examples include but not limited to acetaminophen, alprazolam, atorvastatin calcium, betamethasone acetate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, buprenorphine hydrochloride, butoconazole nitrate, caffeine, calcitriol, carbamazepine, carprofen, celecoxib, cilostazol, clarithromycin, clobetasol Propionate, clofibrate, clopidogrel bisulfate, clotrimazole, dactinomycin, danazol, dapsone, desoximetasone, dexamethasone acetate, dextromethorphan, diazepam, efavirenz, erythromycin estolate, erythromycin ethylsuccinate, erythromycin, estradiol, ethinyl estradiol, ethotoin, ezetimibe, felodipine, fexofenadine hydrochloride, flurbiprofen, fluvoxamine maleate, gemfibrozil, haloperidol, ibuprofen, idarubicin hydrochloride, indapamide, indomethacin, isofluorophate, isotretinoin, ivermectin, lansoprazole, leflunomide, levonorgestrel, lidocaine, loratadine, lovastatin, medroxyprogesterone acetate, metaxalone, methocarbamol, nabumetone, naproxen, niacin, nifedipine, norethindrone acetate, omeprazole, oxandrolone, oxybenzone, oxymetholone, paclitaxel, perphenazine, phenobarbital, phenyloin, pimozide, pitavastatin, prednisolone, prednisolone tebutate, prochlorperazine, progesterone, propoxyphene napsylate, risperidone, ritonavir, lopinavir, and simvastatin.
  • The amount of an excipient employed will depend upon how much active agent is to be used. One excipient can perform multi-functionally. Examples of excipients include but not limited to retarding agent, binder, filler, diluents, lubricant or a mixture thereof.
  • Retarding agent is any substance retards the drug release to produce the controlled-release effect. Examples of retarding agent include but not limited to wax, hydrogel polymer, and many other water-insoluble materials. In the invention, the hydrogel polymer is the key retarding agent.
  • Binders include, but are not limited to, starches such as potato starch, wheat starch, corn starch; microcrystalline cellulose; celluloses such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, sodium carboxy methylcellulose; natural gums like acacia, alginic acid, guar gum; liquid glucose, dextrin, povidone, syrup, polyethylene oxide, polyvinyl pyrrolidone, poly-N-vinyl amide, polyethylene glycol, gelatin, poly propylene glycol, tragacanth, combinations thereof and other materials known to one of ordinary skill in the art and mixtures thereof.
  • Fillers or diluents, which include, but are not limited to sugar, dextrates, dextrin, dextrose, fructose, lactitol, mannitol, sucrose, starch, lactose, xylitol, sorbitol, talc, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic or tribasic, calcium sulphate, and the like can be used.
  • Lubricants may be selected from, but are not limited to, those conventionally known in the art such as magnesium, aluminum or calcium or zinc stearate, polyethylene glycol, glyceryl behenate, mineral oil, sodium stearyl fumarate, stearic acid, hydrogenated vegetable oil and talc.
  • Glidants include, but are not limited to, silicon dioxide; magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate, calcium silicate, magnesium silicate, colloidal silicon dioxide, silicon hydrogel and other materials known to one of ordinary skill in the art.
  • Sweeteners may also be added to the composition. Examples of sweeteners include but not limited to glucose, stevia extracts, acesulfame potassium, aspartame, neotame, saccharin and sucralose.
  • The pharmaceutical dosage form of the invention may also be optionally coated with moisture-barrier film, sugar coating, enteric coating, bioadhesive coating and other coatings known in the art. These coatings help pharmaceutical formulations to release the drug at the required site of action. In one example, the additional coating prevents the dosage from contacting the mouth or esophagus. In another example, the additional coating remains intact until reaching the small intestine or colon (e.g., an enteric coating).
  • These coatings comprise one or more excipients selected from a group consisting of coating agents, plasticizers, channeling agents, opacifiers, taste-masking agents, fillers, polishing agents, coloring agents, anti-tacking agents and the like.
  • Coating agents which are useful in the coating process, include, but are not limited to, polysaccharides such as maltodextrin, alkyl celluloses such as methyl or ethyl cellulose, cellulose acetate, hydroxyalkylcelluloses (e.g. hydroxypropylcellulose or hydroxypropylmethylcelluloses); polyvinylpyrrolidone, acacia, corn, sucrose, gelatin, shellac, cellulose acetate pthalate, lipids, synthetic resins, acrylic polymers, OPADRY® coating systems, polyvinyl alcohol (PVA), copolymers of vinylpyrrolidone and vinyl acetate (e.g. marketed under the brand name of PLASDONE®) and polymers based on methacrylic acid such as those marketed under the brand name of EUDRAGIT®. These may be applied from aqueous or non-aqueous systems or combinations of aqueous and non-aqueous systems as appropriate.
  • Additives can be included along with the film formers to obtain satisfactory films. These additives can include plasticizers such as dibutyl phthalate, triethyl citrate, polyethylene glycol (PEG) and the like, channeling agents such as surfactants, short-chain water-soluble polymers, salts and the like, antitacking agents such as talc, stearic acid, magnesium stearate and colloidal silicon dioxide and the like, fillers such as talc, precipitated calcium carbonate, polishing agents such as Beeswax, carnauba wax, synthetic chlorinated wax and opacifying agents such as titanium dioxide and the like. All these excipients can be used at levels well known to the persons skilled in the art.
    • EXAMPLES OF INVENTION
  • The foregoing examples are illustrative embodiments of the invention and are merely exemplary. A person skilled in the art may make variations and modifications without deviating from the spirit and scope of the invention. All such modifications and variations are intended to be included within the scope of the invention.
    • Example 1
  • Duloxetine hydrochloride and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with a pharmaceutically acceptable carrier, compressed into a tablet.
    • Example 2
  • A portion of metaxalone and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with another portion of metaxalone and a pharmaceutically acceptable carrier, compressed into a tablet.
    • Example 3
  • A portion of clopidogrel bisulfate and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with another portion of metaxalone and a pharmaceutically acceptable carrier, compressed into a tablet.
    • Example 4
  • Duloxetine hydrochloride and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with bupropion hydrochloride and a pharmaceutically acceptable carrier, compressed into a tablet.
    • Example 5
  • Duloxetine hydrochloride and polyvinylpyrrolidone are co-dissolved in methanol. Homogenization is applied to the mixture, as purified water is added gradually till the solution turns to turbid. The suspension is then spray-died, and passed through a 20 mesh screen. The screened particle is then mixed with a tranquilizer and a pharmaceutically acceptable carrier, compressed into a tablet.

Claims (12)

We claim:
1. An oral solid particle essentially consisting of an amorphous structure and a submicron domain, wherein the amorphous structure comprises a drug and an amphiphilic polymer, wherein the submicron domain essentially consists of a drug, and wherein the ratio of the amorphous structure to the submicron domain is 0.1:5 to 1:1
2. An oral solid particle essentially consisting of an amorphous structure and a submicron domain, wherein the amorphous structure comprises a drug and a polyvinylpyrrolidone, wherein the submicron domain essentially consists of a drug, and wherein the ratio of the amorphous structure to the submicron domain is 1:50 to 1:4, and wherein the average diameter of the oral particle is from mesh 20 to mesh 100.
3. An oral solid particle essentially consisting of an amorphous structure and a submicron domain, wherein the amorphous structure comprises a drug and a polyvinylpyrrolidone, wherein the submicron domain essentially consists of a drug, wherein the ratio of the amorphous structure to the submicron domain is 1:50 to 1:4, wherein the average diameter of the submicron domain is about 100 nm, and wherein the average diameter of the oral particle is from mesh 20 to mesh 100.
4. The oral particle as claimed in claims 1-3, wherein more than 30 parts water is needed to dissolve 1 part drug.
5. The oral particle as claimed in claims 1-3, wherein more than 100 parts water is needed to dissolve 1 part drug.
6. The oral particle as claimed in claims 1-3, wherein more than 1000 parts water is needed to dissolve 1 part drug.
7. The oral particle as claimed in claims 1-3, wherein more than 10,000 parts water is needed to dissolve 1 part drug.
8. The oral particle as claimed in claim 3, wherein the drug is selected from a group consisting of acetaminophen, alprazolam, atorvastatin calcium, betamethasone acetate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, buprenorphine hydrochloride, butoconazole nitrate, caffeine, calcitriol, carbamazepine, carprofen, celecoxib, cilostazol, clarithromycin, clobetasol Propionate, clofibrate, clopidogrel bisulfate, clotrimazole, dactinomycin, danazol, dapsone, desoximetasone, dexamethasone acetate, dextromethorphan, diazepam, efavirenz, erythromycin estolate, erythromycin ethylsuccinate, erythromycin, estradiol, ethinyl estradiol, ethotoin, ezetimibe, felodipine, fexofenadine hydrochloride, flurbiprofen, fluvoxamine maleate, gemfibrozil, haloperidol, ibuprofen, idarubicin hydrochloride, indapamide, indomethacin, isofluorophate, isotretinoin, ivermectin, lansoprazole, leflunomide, levonorgestrel, lidocaine, loratadine, lovastatin, medroxyprogesterone acetate, metaxalone, methocarbamol, nabumetone, naproxen, niacin, nifedipine, norethindrone acetate, omeprazole, oxandrolone, oxybenzone, oxymetholone, paclitaxel, perphenazine, phenobarbital, phenyloin, pimozide, pitavastatin, prednisolone, prednisolone tebutate, prochlorperazine, progesterone, propoxyphene napsylate, risperidone, ritonavir, lopinavir, and simvastatin.
9. The oral particle as claimed in claim 3, wherein the drug is niacin.
10. The oral particle as claimed in claim 3, wherein the drug is acetaminophen.
11. The oral particle as claimed in claim 3, wherein the drug is metaxalone.
12. The oral particle as claimed in claim 3, wherein the drug is clopidogrel bisulfate.
US13/663,350 2012-06-26 2012-10-29 Oral particle consisting of an amorphous structure and a submicron domain Abandoned US20130344116A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/663,350 US20130344116A1 (en) 2012-06-26 2012-10-29 Oral particle consisting of an amorphous structure and a submicron domain
US13/680,070 US20130344148A1 (en) 2012-06-26 2012-11-18 Oral Composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/533,410 US8313774B1 (en) 2012-06-26 2012-06-26 Oral solid composition
US13/663,350 US20130344116A1 (en) 2012-06-26 2012-10-29 Oral particle consisting of an amorphous structure and a submicron domain

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/533,410 Continuation US8313774B1 (en) 2012-06-26 2012-06-26 Oral solid composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/680,070 Continuation US20130344148A1 (en) 2012-06-26 2012-11-18 Oral Composition

Publications (1)

Publication Number Publication Date
US20130344116A1 true US20130344116A1 (en) 2013-12-26

Family

ID=47148017

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/533,410 Expired - Fee Related US8313774B1 (en) 2012-06-26 2012-06-26 Oral solid composition
US13/663,350 Abandoned US20130344116A1 (en) 2012-06-26 2012-10-29 Oral particle consisting of an amorphous structure and a submicron domain
US13/680,070 Abandoned US20130344148A1 (en) 2012-06-26 2012-11-18 Oral Composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/533,410 Expired - Fee Related US8313774B1 (en) 2012-06-26 2012-06-26 Oral solid composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/680,070 Abandoned US20130344148A1 (en) 2012-06-26 2012-11-18 Oral Composition

Country Status (1)

Country Link
US (3) US8313774B1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106265666A (en) * 2016-09-18 2017-01-04 西安交通大学 Improve compositions of insoluble drug loratadine release and its preparation method and application
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
CN107536804A (en) * 2016-06-28 2018-01-05 浙江普利药业有限公司 Fexofenadine hydrochloride dry suspensoid agent and preparation method thereof
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
JP2021518416A (en) * 2018-03-19 2021-08-02 ホビオネ サイエンティア リミテッド New forms of ivermectin and its production process

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8313774B1 (en) * 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
CN110917156A (en) * 2019-12-18 2020-03-27 乐普制药科技有限公司 Ezetimibe buccal tablet and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562069A (en) * 1983-05-21 1985-12-31 Bayer Aktiengesellschaft Two-phase formulation
US4892730A (en) * 1981-10-29 1990-01-09 Bayer Aktiengesellschaft Processes for preparation of solid, rapidly released medicament preparations containing dihydropyridines
US8313774B1 (en) * 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654296A (en) 1984-07-26 1987-03-31 E. I. Du Pont De Nemours And Company Process for making lithographic film using photopolymer diffusion modulation layer for pigmented bottom layer
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
DE59206324D1 (en) 1991-12-05 1996-06-20 Alfatec Pharma Gmbh PHARMACEUTICAL APPLICABLE NANOSOL AND METHOD FOR THE PRODUCTION THEREOF
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5651983A (en) 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5843479A (en) 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5514663A (en) 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
AU7961094A (en) 1993-10-19 1995-05-08 Procter & Gamble Company, The Picosulphate dosage form
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
PT1165051E (en) * 1999-03-19 2003-11-28 Ranbaxy Lab Ltd PROCESS FOR THE PREPARATION OF A BIODISPONABLE ORAL DOSAGE FORM OF CEFUROXIMA AXETIL
US20010053791A1 (en) 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
DE10046541A1 (en) 2000-09-19 2002-03-28 Knoll Ag Oral dosage form useful as nutritional supplement or medicament comprises solid dispersion of ubiquinone in thermoplastic matrix
WO2004056359A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
KR20060096076A (en) 2003-11-14 2006-09-05 화이자 프로덕츠 인크. Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
EP2240173A4 (en) * 2008-01-25 2013-07-17 Alphapharm Pty Ltd Delayed release pharmaceutical composition of duloxetine
US8349900B2 (en) 2008-08-07 2013-01-08 Valeant International Bermuda Bupropion hydrobromide polymorphs
US20090220590A1 (en) * 2009-04-06 2009-09-03 Ikemefuna Nkanginieme Triple drug combinations for psychiatric patients
PT2442791T (en) 2009-06-16 2020-02-06 Pfizer Dosage forms of apixaban

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892730A (en) * 1981-10-29 1990-01-09 Bayer Aktiengesellschaft Processes for preparation of solid, rapidly released medicament preparations containing dihydropyridines
US4562069A (en) * 1983-05-21 1985-12-31 Bayer Aktiengesellschaft Two-phase formulation
US8313774B1 (en) * 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Drug Bank: Omeprazole" (DB0038), http://www.drugbank.ca/drugs/db00338, pp. 1-15, Accessed 1/23/15. *
Remington: The Science and Practice of Pharmacy, 21st Edition, 2003, pp. 675-676. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
CN107536804A (en) * 2016-06-28 2018-01-05 浙江普利药业有限公司 Fexofenadine hydrochloride dry suspensoid agent and preparation method thereof
CN106265666A (en) * 2016-09-18 2017-01-04 西安交通大学 Improve compositions of insoluble drug loratadine release and its preparation method and application
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11304961B2 (en) 2017-12-18 2022-04-19 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
JP2021518416A (en) * 2018-03-19 2021-08-02 ホビオネ サイエンティア リミテッド New forms of ivermectin and its production process

Also Published As

Publication number Publication date
US8313774B1 (en) 2012-11-20
US20130344148A1 (en) 2013-12-26

Similar Documents

Publication Publication Date Title
JP6934932B2 (en) Solid pharmaceutical composition of androgen receptor antagonist
JP5845173B2 (en) Orally disintegrating tablet composition comprising a combination of a non-opioid and an opioid analgesic
AU2007338359B2 (en) Pharmaceutical formulation comprising neurokinin antagonist
US20130344116A1 (en) Oral particle consisting of an amorphous structure and a submicron domain
JP2007504266A (en) Ziprasidone sustained release dosage form
WO2008064202A2 (en) Modified-release formulations of calcium receptor-active compounds
WO2008070072A2 (en) Carvedilol forms, compositions, and methods of preparation thereof
JP6896738B2 (en) Pharmaceutical composition comprising a phenylaminopyrimidine derivative
AU2006284133A1 (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a pH modifier
US20150118296A1 (en) Controlled release budesonide compositions
TW201609195A (en) Solid antiviral dosage forms
AU2022201196A1 (en) Pharmaceutical composition comprising acetaminophen and ibuprofen
US9968607B2 (en) Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
JP2006507298A (en) Oral sustained-release tablets and methods for making and using the same
US12097185B2 (en) Compositions comprising ciprofloxacin and celecoxib
EP1897537A1 (en) Composition comprising an angiotensin II receptor antagonist
JP2004238348A (en) Itraconazole preparation for oral administration
JP2024539116A (en) Compositions Comprising Ciprofloxacin and Celecoxib
KR20220015437A (en) Modified release formulations of pyrimidinylamino-pyrazole compounds, and methods of treatment
JP2008115083A (en) Coated granule containing tramadol hydrochloride
JP2018184360A (en) Enteric-coated sustained release formulation for oral administration

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION